Institut Curie's TTO is engaged in the creation of new company based on Institut Curie’s research when there is Curie's intellectual property owned (at least partly). Focus is made on the early stages of new companies’ development, including securing initial funding through our strong ties with major seed investment professionals. The support provided includes:
- A personalized accompaniment
- Special conditions on R&D collaborations with Institut Curie
- Privileged access to Institut Curie’s facilities,
- Administrative support…and much more to come !
Institut Curie has contributed to 18 start-ups created to date. Among them, Institut Curie holds shares in 6 (dosisoft, propulse, meiogenix, cytoo, onxeo).Their activity includes developing radiotherapy software, proton therapy devices, microfluidics devices and cell culture devices, delivering services using Institut Curie's bank of xenotransplants, directed meiotic recombination, and developing several new therapies, including new classes of drugs against HIV, a new class of vascular disrupting agents, a new class of anticancer vaccines, and drugs that inhibit DNA repair.